October 5, 2020
Wohl launches clinical trial, one of 25 sites nationally testing COVID-19 treatments
The first investigational agent to be evaluated by ACTIV-2 is LY3819253, an experimental monoclonal antibody treatment made by Lilly Research Laboratories in partnership with AbCellera Biologics.